Combinatorial Drug Treatment in a Model of Fragile X Syndrome using Novel Biomarkers

With a $90,000 grant from FRAXA Research Foundation awarded over 2016-2017, University of California researchers Khaleel Razak, PhD, and Jonathan W. Lovelace, PhD, are exploring drug combinations to limit hypersensitivity to sounds in fragile X mice.

Funding opportunities - FRAXA investigators
$51,000 Grant
Jonathan Lovelace, PhD
FRAXA Postdoctoral Fellow

Khaleel Razak, PhD

Principal Investigator
University of California at Riverside
2016 FRAXA Research Grant
$90,000 over 2 Years

With this grant, we have expanded our work in anesthetized mice to auditory evoked responses of the auditory cortex in awake freely moving mice which have been bred to mimic fragile X syndrome. While these experiments are more difficult to perform, they offer a more translatable outcome measure when compared to humans with FXS, since anesthesia can alter responsiveness of sensory systems and generally eliminate top-down mechanisms of sensory perception.

We next sought to test our EEG outcome measures on candidate drugs to reverse EEG biomarkers which include: CTEP (mglur5 antagonist) and Minocycline (tetracycline derivative which is thought to act through inhibition of MMP9).

At the same time, we have been developing behaviors assays in the lab (Open Field, Elevated Plus Maze, and Novel Object Recognition) with the goal of relating EEG outcome measures to behavioral outcomes. This will allow us to use both behavior and EEG measures to test the effectiveness of drug treatments, but also gives insight into analyzing drug-responders vs non-responders on these different measures. This new information could allow prediction of drug responsiveness based on objective physiological measures before drug administration, a potentially powerful tool for clinical research moving forward.